Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients
Isoniazid (INH), recommended by WHO (World Health Organization) in the treatment of tuberculosis (TB), is metabolized primarily by the genetically polymorphic N-acetyltransferase 2 (NAT2) enzyme. The human population is divided into three different phenotypic groups according to acetylation rate: sl...
Main Authors: | Dr. A. Toure, M. Cabral, A. Niang, C. Diop, A. Garat, L. Humbert, M. Fall, A. Diouf, F. Broly, M. Lhermitte, D. Allorge |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Toxicology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214750016300804 |
Similar Items
-
NAT2 Genotype and Isoniazid Medication in Children
by: Klaus Golka, et al.
Published: (2016-09-01) -
The Influence of NAT2 Genotypes on Isoniazid Plasma Concentration of Pulmonary Tuberculosis Patients in Southern Thailand
by: Usanee Ungcharoen, et al.
Published: (2020-12-01) -
Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy – case report and literature review
by: Stefan Matei Constantinescu, et al.
Published: (2017-09-01) -
NAT2 gene polymorphisms and plasma isoniazid concentration in Vietnamese tuberculosis patients
by: Anh Tuan Le, et al.
Published: (2019-11-01) -
The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism
by: Zoe Rogers, et al.
Published: (2016-09-01)